이수앱지스

086890KOSDAQ

49.0 / 100

Reference Date: 2026-09-08

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 1.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Isu Appgis primarily operates in the pharmaceutical sector, focusing on key products such as Absorcin (for Gaucher disease), Fabrazyme (for Fabry disease), and Clotyplast (an antibody therapy for cardiovascular conditions). In 2024, sales reached 60.3 billion won, a 11% increase from the previous year, with product sales accounting for 86.3% of total revenue. Product prices have remained stable over the past three years.

Number of Employees

190people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.21Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-9.92Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.96Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲78.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 3,410Won52-week high 6,24052-week low 2,975

1-month return3.0Point

1m 1.34% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral기업설명회(IR)개최2026-08-10